Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

IPierian spins off True North and allocates part of $30mm to Series A; Series A disclosed as $22mm

Executive Summary

True North Therapeutics Inc. has spun off from iPierian Inc. to pursue the latter’s monoclonal antibody program targeting the complement pathway. IPierian concurrently received $30mm in financing, most of which will go toward its Series C, with a smaller portion allocated to True North’s Series A round. SR One, Kleiner Perkins Caufield & Byers, and MPM Capital co-led the fundraising, with participation from FinTech Global Capital, Highland Capital Partners, Google Ventures, Mitsubishi UFJ Capital, Biogen Idec New Ventures, and ATEL Ventures. An SR One representative joined both iPierian and True North’s boards.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies